Cat. No.: HY-B0330B

Levofloxacin hydrochloride

(Synonyms: (-)-Ofloxacin hydrochloride)

38 Cited Publications

Customer Review

Based on 38 publication(s) in Google Scholar

Levofloxacin hydrochloride is an orally active antibiotic. Levofloxacin inhibits DNA gyrase and topoisomerase IV activity, inducing Apoptosis. Levofloxacin hydrochloride has antibacterial activity against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride exhibits anticancer activity against lung cancer. Levofloxacin hydrochloride has anti-acnegenic, anxiogenic, and analgesic effects. Levofloxacin hydrochloride shortens sleep duration in mice. Levofloxacin hydrochloride can be used in the research of infectious diseases (such as tuberculosis, chronic periodontitis, bacterial infections associated with stable COPD, and BK viremia) and lung cancer.

For research use only. We do not sell to patients.

Purity: 99.99%
CAS No.: 177325-13-2
Formula: C₁₈H₂₁ClFN₃O₄
Molecular Weight:397.83

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Levofloxacin hydrochloride Chemical Structure

CAS No.: 177325-13-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (38)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

TOPO IV

All Antibiotic Isoforms :

All DNA/RNA Synthesis Isoforms :

All Topoisomerase Isoforms :

In Vitro

Levofloxacin hydrochloride inhibits the growth of 18 drug-susceptible Mycobacterium tuberculosis strains with MICs ranging from 0.25 to 1.0 μg/mL and a MIC₅₀ of 0.5 μg/mL^[4].
Levofloxacin (24 h) hydrochloride exhibits strong bactericidal activity against biofilm-forming sessile cells of Pseudomonas aeruginosa^[8].
Levofloxacin (50-200 μg/mL; 24-72 h) hydrochloride inhibits proliferation and induces apoptosis of lung cancer cells (A549, H3255, NCL-69, H460) through inducing mitochondrial dysfunction and oxidative damage^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Levofloxacin (10.7 mg/kg; i.p., once daily for 10 days or 3 weeks) hydrochloride time-dependently induces toxic effects on liver and heart in albino mice^[3].
Levofloxacin (50-300 mg/kg; p.o. via esophageal cannula; six times weekly; 4 weeks) hydrochloride exerts dose-dependent anti-Mycobacterium tuberculosis activity in female outbred Swiss mice^[4].
Levofloxacin (10-40 mg/kg, i.p.) hydrochloride exerts anxiogenic-like effect in rats and shortens Pentobarbital-induced sleeping time, exhibits analgesic activity in mice^[10].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Matured male Albino mice^[3]
Dosage:

10.7 mg/kg
Administration:

Intraperitoneal injection; 10.7 mg/kg, once daily for 10 days or 3 weeks.
Result:

Induced severe congestion of blood vessels in the portal area, central veins with inflammatory cells infiltration, necrosis with pyknosis of cardiac muscle nuclei and apoptosis, degeneration and necrosis of hepatocytes.

Chemical Information

CAS No. 177325-13-2
Appearance Solid
Molecular Weight 397.83
Formula C₁₈H₂₁ClFN₃O₄
Color White to off-white
SMILES

[H]Cl.O=C(C(C1=O)=CN2[C@@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O
Synonyms

(-)-Ofloxacin hydrochloride
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (38)

All Microbiological AssayCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Nat Commun

Phenotypic drug susceptibility testing for Mycobacterium tuberculosis variant bovis BCG in 12 hours. [Abstract]

2025 May 10;16(1):4366. PMID: 40348759

Levofloxacin hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 10;16(1):4366. [Abstract]

M. bovis BCG Russia WT in LFX (0-25 h) 1 mg/L.

Levofloxacin hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 10;16(1):4366. [Abstract]

M. bovisBCG Russia FQ^R in LFX (0-25 h) 1 mg/L.
Nat Commun

Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]

2022 Mar 2;13(1):1116. PMID: 35236849
Acta Pharm Sin B

Generation and applications of an expandable and mature hiPSC-derived liver organoid. [Abstract]

2025 Dec;15(12):6382-6398. PMID: 41477334

Levofloxacin hydrochloride purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Dec;15(12):6382-6398. [Abstract]

Levofloxacin exhibited toxicity at 25 × C_max, which resulted in a 65% reduction in organoid cell viability.
Sci Adv

Quantitative prediction of siRNA complexation by ionizable drugs enables their codelivery in nanoparticles. [Abstract]

2026 Jun 12;12(24):eaed2731. PMID: 42284421
Chem Eng J

2026 Feb 12.
J Exp Med

Antibiotic use in early life impairs MAIT cell-mediated immunity in adulthood. [Abstract]

2026 Mar 2;223(3):e20241287. PMID: 41400657
EBioMedicine

Diverse impacts of different rpoB mutations on the anti-tuberculosis efficacy of capreomycin. [Abstract]

2025 Jul:117:105776. PMID: 40449326

Levofloxacin hydrochloride purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2025 Jul:117:105776. [Abstract]

Killing curves of different Ms rpoB mutants after exposure to LFX (0-48 h) at 1 μg/mL (5 × MIC) in 7H9 medium.
Food Res Int

Prevalence, plasmid transmission, and chromosomal integration of blaCTX-M genes in Salmonella isolated from retail chicken and pork meats in China. [Abstract]

2026 Aug 31:238:119421. PMID: 42215089
Clin Chem

Discovering Cross-Reactivity in Urine Drug Screening Immunoassays through Large-Scale Analysis of Electronic Health Records. [Abstract]

2019 Dec;65(12):1522-1531. PMID: 31578215
Emerg Microbes Infect

AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria. [Abstract]

2024 Dec;13(1):2321981. PMID: 38422452
Virulence

Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]

2026 Dec 31;17(1):2646808. PMID: 41838520
Commun Biol

The acetyltransferase CysE modulates virulence and drug resistance of Mycobacterium tuberculosis by interfering with oxidative stress responses. [Abstract]

2025 Oct 6;8(1):1425. PMID: 41053365
Results Chem

2024 Oct.
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Antibiotics (Basel)

Antibacterial Activity of the Novel Drug Gepotidacin against Stenotrophomonas maltophilia-An In Vitro and In Vivo Study. [Abstract]

2022 Feb 1;11(2):192. PMID: 35203795

Levofloxacin hydrochloride purchased from MedChemExpress. Usage Cited in: Antibiotics (Basel). 2022 Feb 1;11(2):192. [Abstract]

Determined minimum inhibitory concentrations (MICs) of Gepotidacin, Levofloxacin, Moxifloxacin, and Co-trimoxazole against S. maltophilia.
Int J Antimicrob Agents

Elucidating adaptive compensatory tigecycline resistance mechanisms of RamA, RarA and SoxS in Klebsiella pneumoniae. [Abstract]

2025 Oct;66(4):107551. PMID: 40499596
PLoS Pathog

Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]

2026 Jan 26;22(1):e1013903. PMID: 41587213
Toxics

The Acute Toxicity and Cardiotoxic Effects of Levofloxacin on Zebrafish (Danio rerio). [Abstract]

2025 Feb 5;13(2):122. PMID: 39997937
ACS Infect Dis

Lusutrombopag as a Repurposing Drug in Combination with Aminoglycosides against Vancomycin-Resistant Enterococcus. [Abstract]

2024 Apr 12;10(4):1327-1338. PMID: 38567846
Antimicrob Agents Chemother

Dihydrotanshinone I Is Effective against Drug-Resistant Helicobacter pylori In Vitro and In Vivo. [Abstract]

2021 Feb 17;65(3):e01921-20. PMID: 33318002
Microbiol Spectr

Montelukast treats Streptococcus pneumoniae-induced sepsis via antibacterial and anti-inflammatory activities. [Abstract]

2025 Oct 15:e0122125. PMID: 41090944
Microbiol Spectr

Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan. [Abstract]

2025 Jul;13(7):e0307424. PMID: 40387379
AMB Express

Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms. [Abstract]

2024 Dec 24;14(1):141. PMID: 39718732
J Med Virol

Drug Repurposing: In Vitro Evaluation of Simeprevir as a Novel Antiviral Drug Against Severe Fever With Thrombocytopenia Syndrome Virus. [Abstract]

2025 Oct;97(10):e70655. PMID: 41117261
Water

2025 Jun 6.
Infect Drug Resist

2026 May 8;19.
Eur J Clin Microbiol Infect Dis

Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) for carbapenemase-producing Klebsiella pneumoniae with focus on KPC variants. [Abstract]

2025 Sep 29. PMID: 41023358
Infect Genet Evol

Polymyxin B combined with amikacin delays the resistance of Klebsiella pneumoniae to polymyxin B by modulating the expression of NlpE. [Abstract]

2025 Sep:133:105780. PMID: 40480594
PLoS One

In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex. [Abstract]

2024 Apr 18;19(4):e0298577. PMID: 38635685
Future Microbiol

Synergistic drug strategy against mastitis-associated MRSA strains. [Abstract]

2025 Oct 13:1-10. PMID: 41082411
Chin J Traumatol

The cytochrome P4501A1 (CYP1A1) inhibitor bergamottin enhances host tolerance to multidrug-resistant Vibrio vulnificus infection. [Abstract]

2024 Sep;27(5):295-304. PMID: 38981821
Diagn Microbiol Infect Dis

A rapid bacterial labeling method for phenotypic antimicrobial susceptibility testing. [Abstract]

2026 Feb;114(2):117181. PMID: 41205476
Res Sq

2026 Mar 9.
SSRN

2025 Oct 14.
Res Sq

2025 Aug 05.
bioRxiv

2025 January 19.
bioRxiv

2024 May 10.

Solvent & Solubility

In Vitro:

H₂O : ≥ 100 mg/mL (251.36 mM)

DMSO : 5.83 mg/mL (14.65 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5136 mL

12.5682 mL

25.1364 mL

5 mM

0.5027 mL

2.5136 mL

5.0273 mL

10 mM

0.2514 mL

1.2568 mL

2.5136 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Drlica K, et al. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. [Content Brief]

[2]. Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52. [Content Brief]

[3]. Rand A, et al. Effect of levofloxacin on some body tissues in mice. Effect of levofloxacin on some body tissues in mice. Iraqi Journal of Veterinary Sciences, 2021.

[4]. JI B, et al. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Jun;39(6):1341-4. [Content Brief]

[5]. Siva R, et al. Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis. 2014 Feb 7;9:179-86. [Content Brief]

[6]. Pradeep AR, et al. Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent. 2015 Aug;6(3):170-8. [Content Brief]

[7]. Lee BT, et al. Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial. Clin J Am Soc Nephrol. 2014 Mar;9(3):583-9. [Content Brief]

[8]. Ishida H, et al. In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1998 Jul;42(7):1641-5. [Content Brief]

[9]. Song M, et al. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through inducing mitochondrial dysfunction and oxidative damage. Biomed Pharmacother. 2016 Dec;84:1137-1143. [Content Brief]

[10]. Erden BF, et al. Antidepressant, anxiogenic, and antinociceptive properties of levofloxacin in rats and mice. Pharmacol Biochem Behav. 2001 Mar;68(3):435-41. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	2.5136 mL	12.5682 mL	25.1364 mL	62.8409 mL
	5 mM	0.5027 mL	2.5136 mL	5.0273 mL	12.5682 mL
	10 mM	0.2514 mL	1.2568 mL	2.5136 mL	6.2841 mL
H₂O	15 mM	0.1676 mL	0.8379 mL	1.6758 mL	4.1894 mL
	20 mM	0.1257 mL	0.6284 mL	1.2568 mL	3.1420 mL
	25 mM	0.1005 mL	0.5027 mL	1.0055 mL	2.5136 mL
	30 mM	0.0838 mL	0.4189 mL	0.8379 mL	2.0947 mL
	40 mM	0.0628 mL	0.3142 mL	0.6284 mL	1.5710 mL
	50 mM	0.0503 mL	0.2514 mL	0.5027 mL	1.2568 mL
	60 mM	0.0419 mL	0.2095 mL	0.4189 mL	1.0473 mL
	80 mM	0.0314 mL	0.1571 mL	0.3142 mL	0.7855 mL
	100 mM	0.0251 mL	0.1257 mL	0.2514 mL	0.6284 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Levofloxacin hydrochloride

38 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Levofloxacin hydrochloride

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Lung Cancer Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Orthopoxvirus Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Anti-tuberculosis Compound Library

Cell Death Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Levofloxacin hydrochloride

All Antibiotic Isoforms

All DNA/RNA Synthesis Isoforms

All Topoisomerase Isoforms

Biological Activity

Chemical Information

Publications (38)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Levofloxacin hydrochloride Related Classifications

HY-B0330B Related Classifications